Continuous Temperature Telemonitoring of Patients With COVID-19 and Other Infectious Diseases in Hospital at Home Using Viture

COVID-19 Clinical Trial

— Viture  

Official title:

Temperature Telemonitoring for Hospital at Home (HaH) Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05959928
• Other study ID #: 859/20/EC
• Status: Completed
• Start date: February 9, 2021
• Est. completion date: June 2, 2021

Study information

• Verified date: July 2023
• Source: Vitio Medical S.L.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this cohort study is to validate Viture®, a continuous temperature telemonitoring system, evaluating the level of agreement with a standard commercially available digital axillary thermometer. The study also aims to evaluate the safety and comfort of the system and to evaluate the impact that the introduction of Viture has on the health care practice of a HaH unit. Furthermore, the advantages of Viture compared to the standard method will be evaluated.

Description:

Body temperature is a key vital sign in the follow-up of patients admitted to Hospital at Home (HaH) units with COVID-19 and other infectious diseases. Continuous telemonitoring of temperature can lead to earlier detection of fever and patient deterioration that facilitates early decision making.

In the first day of the study, the patients will be given a study kit of Viture System with the following content:

• Viture Device.

• Digital reference thermometer for control Spot Temperature Measurements (STMs)

• Smartphone with Viture Mobile App installed.

• Device user manual in quick guide format.

• Home data collection notebook (HDCN)

The HaH team will place Viture Device on the patient and train the patient and/or caregiver. They will ask patients to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the HDCN.

In the case that the bracelet is removed, or the patient experience discomfort, they will be asked to fill in the incident in the HDCN. Mild incidents are considered skin alterations such as redness and chafing and severe incidents are considered hematomas and ulcers.

The HaH team on duty will collect all Viture notifications, registering the date, time, and follow-up for each febrile episode. The patient and/or caregiver could be contacted to request a control STM.

A statistical analysis of agreement between the digital reference thermometer (Gold standard) and Viture will be carried out. The non-parametric Wilcoxon signed rank test will be used to evaluate the average agreement between the two methods, and the Bland Altman method will be used to evaluate the agreement between individual measurements. Both analyses will be validated with a 95% confidence interval.

To explore the true potential of Viture, an analysis of the febrile episodes experienced by patients during the clinical study will be performed. Febrile episodes will be characterized by their maximum temperature and duration. To assess the impact of Viture notifications, the data registered on the follow-up of febrile episodes will be analyzed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 209
• Est. completion date: June 2, 2021
• Est. primary completion date: June 2, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• be more than 18 years old.

• to be able to legally give informed consent.

• not to have limitations to the use of the Viture Device due to their physical conditions or interference with other devices.

Exclusion Criteria:

• To be monitored for less than 2 days.

• To have less than 4 valid control Spot Temperature Measurements (STM). A valid control STM is considered a temperature measured with the reference thermometer that has a simultaneous (within 1 minute) Viture Temperature Measurement (VTM)

Related Conditions & MeSH terms

• Bacteremia
• Cellulitis
• Communicable Diseases
• COVID-19
• Infections
• Infectious Disease
• Respiratory Infection
• Respiratory Tract Infections
• Urinary Tract Infections

Intervention

Device:
• Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely
The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)

Locations

Country	Name	City	State
Spain	Hospital Universitario de Navarra	Pamplona	Navarra

Sponsors (3)

Lead Sponsor	Collaborator
Vitio Medical S.L.	Hospital Universitario de Navarra, NAVARRABIOMED

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Verify that, under normal conditions of use, the performance of Viture for body temperature measurement is equivalent to the devices used in the standard practice.	Comparison between the temperatures recorded remotely by Viture and a control digital thermometer used in the follow-up of patients in Hospital at Home, both COVID-19 patients and patients with other diseases who benefit from body temperature monitoring.	3 measurements per day
Secondary	Evaluate the safety, usability and comfort of Viture Device	Record usability experience and negative sensations expressed by users due to the use of Viture, such as discomfort or skin irritation in the area where the device is placed.	Through study completion, an average of 5 days